WO2000056716A1 - Synthesis of 3-amino-3-aryl propanoates - Google Patents

Synthesis of 3-amino-3-aryl propanoates Download PDF

Info

Publication number
WO2000056716A1
WO2000056716A1 PCT/US2000/007493 US0007493W WO0056716A1 WO 2000056716 A1 WO2000056716 A1 WO 2000056716A1 US 0007493 W US0007493 W US 0007493W WO 0056716 A1 WO0056716 A1 WO 0056716A1
Authority
WO
WIPO (PCT)
Prior art keywords
formula
compound
aryl
heteroaryl
alkyl
Prior art date
Application number
PCT/US2000/007493
Other languages
French (fr)
Inventor
Ahmed F. Abdel-Magid
Judith H. Cohen
Cynthia A. Maryanoff
Frank John Villani, Jr.
Hua M. Zhong
Original Assignee
Ortho-Mcneil Pharmaceutical, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to NZ514379A priority Critical patent/NZ514379A/en
Priority to CA002367971A priority patent/CA2367971A1/en
Priority to JP2000606578A priority patent/JP2002540101A/en
Priority to EP00918213A priority patent/EP1163223A1/en
Priority to MXPA01009617A priority patent/MXPA01009617A/en
Priority to BR0009856-6A priority patent/BR0009856A/en
Application filed by Ortho-Mcneil Pharmaceutical, Inc. filed Critical Ortho-Mcneil Pharmaceutical, Inc.
Priority to SK1359-2001A priority patent/SK13592001A3/en
Priority to UA2001096537A priority patent/UA72755C2/en
Priority to KR1020017012070A priority patent/KR20020015031A/en
Priority to AU39064/00A priority patent/AU776300B2/en
Publication of WO2000056716A1 publication Critical patent/WO2000056716A1/en
Priority to HR20010768A priority patent/HRP20010768A2/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C227/00Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C227/30Preparation of optical isomers
    • C07C227/32Preparation of optical isomers by stereospecific synthesis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/07Optical isomers

Definitions

  • the invention relates to a process of preparing a compound of the formula
  • R 1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl and R 2 is hydrogen, alkyl or aralkyl, or salt thereof.
  • Compounds of Formula I are useful as intermediates in the synthesis of, inter alia, compounds described in WO 97/41102.
  • Compounds described in WO 97/41102 are antagonists of the platelet fibrinogen receptor (gp)
  • Ilb/IIIa antagonist and thus are useful for treating platelet-mediated thrombotic disorders such as arterial and venous thrombosis, acute myocardial infarction, reocclusion following thrombolytic therapy and angioplasty, inflammation, unstable angina and vaso-occlusive disorders.
  • Known methods for preparing compounds of Formula I include an asymmetric Michael addition of lithium (R) -N- (trimethylsilyl) - (1) -phenethylamide to ethyl 3-pyridyl acrylate to give the ethyl ⁇ -aminoester disclosed in US Patent 5,254,573. This process results in inefficient formation of lithium amide and difficult removal of N- ( - methylbenzyl ) group .
  • J. Org. Chem. vol. 61, p. 2222 discloses a process wherein the lithium enolate of ethyl acetate is added to an enantiomoric sulfinimine, the product of which is purified by chromatography and deprotected under acidic conditions to afford the ⁇ -amino ester in greater than 90% ee .
  • the need for chromatographic purification makes this process unattractive for large-scale production.
  • WO 98/02410 discloses a process of stereoselective addition of the Reformatsky reagent prepared from t- butylbromoacetate to the enantiomeric imine prepared from 3-pyridine carboxaldehyde and (R) -2-phenylglycinol .
  • Use of oxidizing agents makes this process unattractive for large-scale production.
  • WO 97/41102 discloses enzymatic resolution of the ( ⁇ ) ⁇ - phenylacetamido acid using penicillin amidase to afford the S-acid. This process, which utilizes enzymes, is inefficient and impractical for large scale production. Thus there exists a need for a process which is compatible with large scale production needs and which achieves acceptable levels of purity and yield.
  • the invention relates to a process for preparing a compound of the formula
  • R 1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl and R 2 is hydrogen, alkyl or aralkyl, or salt thereof,
  • R 5 is hydrogen or alkoxy, under conditions of reduced pressure, such that the reaction solution boils at temperatures of between about 40° and about 65 °C, in an inert solvent, which solvent under reduced pressure is capable of azeotropic removal of water, to form the compound of formula IV,
  • compound la can further be converted to a compound of formula lb or a salt thereof,
  • R 2" is hydrogen via saponification of the ester.
  • alkyl whether used alone or as part of a substituent group, include straight and branched chains.
  • alkyl radicals include methyl, ethyl, n-propyl , isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, n-hexyl and the like.
  • "lower" when used with alkyl means a carbon-chain composition of 1-4 carbon atoms.
  • alkoxy shall denote an oxygen ether radical of the above described straight or branched chain alkyl groups. For example, methoxy, ethoxy, n-propoxy, sec-butoxy, t-butoxy, n- hexyloxy and the like.
  • aryl shall refer to unsubstituted carbocylic aromatic groups such as phenyl, naphthyl, and the like.
  • the aryl group may be substituted with at least one substituent.
  • Suitable substituents on the aryl group are selected independently from the group consisting of halogen, hydroxy, lower alkyl, lower alkoxy, lower aralkyl, -NR 3 2 , wherein R 3 is a lower alkyl; R 4 CONH, wherein R 4 is phenyl or a lower alkyl; and -OC(0)R 6 wherein R 6 is hydrogen, alkyl or aralkyl.
  • heteroaryl shall denote any five or six membered monocyclic aromatic ring structure containing at least one heteroatom selected from 0, N and S or a bicyclic system wherein the monocyclic heteroaryl is fused to an aryl or monocyclic heteroaryl.
  • heteroaryl groups include, but are not limited to, pyrrolyl , pyridyl, pyrazinyl, pyrimidinyl , pyrazolyl, pyridazinyl, furanyl, pyranyl , imidazolyl, thienyl, oxazolyl, isothiazolyl , isoxazolyl, furazanyl, benzothienyl , benzofuranyl , indolyl , isoindolyl, indolizinyl, indazolyl , purinyl, isoquinolyl , quinolyl , isothiazolyl, and the like.
  • the heteroaryl may be substituted with at least one substituent.
  • Suitable substituents on the heteroaryl group are selected independently from the group consisting of halogen, hydroxy, lower alkyl, lower alkoxy, lower aralkyl, -NR 3 2 , wherein R 3 is a lower alkyl; R 4 C0NH, wherein R 4 is phenyl or a lower alkyl, and
  • R 6 is hydrogen, alkyl or aralkyl; preferably halogen or lower alkyl .
  • the heteroaryl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure.
  • the heteroaryl is selected from the group consisting of pyridyl, pyrimidinyl, furanyl and thienyl.
  • aralkyl shall mean any lower alkyl group substituted with an aryl group such as phenyl, naphthyl and the like.
  • halogen shall mean chlorine, bromine, fluorine and iodine.
  • Compound of formula IV because of the presence of a double bond, can exist in either the cis or the trans configuration or as a mixture of the two configurations.
  • enantiomeric excess or ee shall mean the excess amount of one enantiomer over another enantiomer.
  • the enantiomeric excess (expressed as a percentage) is calculated as:
  • the enantiomeric excess of the desired enantiomer of formula III is at least 90 percent ee, more preferably at least 98 percent ee, most preferably 99 percent ee .
  • R 1 is phenyl, pyrimidyl , unsubstituted or substituted pyridyl, napthyl or 3,5- dichlorophenyl , more preferably 2 -pyridyl, 3 -pyridyl or 4- pyridyl, most preferably 3 -pyridyl.
  • R 2 is preferably lower alkyl , more preferably methyl or ethyl .
  • the invention relates to a process for preparing a compound of the formula I
  • R 1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl and R 2 is hydrogen, alkyl or aralkyl, or salt thereof,
  • R 1 is as described above and R 2' is alkyl or aralkyl, with a compound of the formula III
  • R 5 is hydrogen or alkoxy, preferably hydrogen or methoxy, under conditions of reduced pressure, such that the reaction solution boils at temperatures of between about 40° and about 65 °C , in an inert solvent, which solvent under reduced pressure is capable of azeotropic removal of water, to form the compound of formula IV
  • R 2' is alkyl or aralkyl or a salt thereof .
  • compound la can further be converted to a compound of formula lb or a salt thereof, wherein R 2" is hydrogen via saponification of the ester.
  • a compound of formula II a known compound or compound prepared by known methods, (J. Org. Chem . 1975, 40 , 532; J. Org . Chem . 1983, 48 , 5006) is reacted with a compound of formula III, a known compound or compound prepared by known methods , ( Vestn . Mosk . Univ. Ser2 : Khim .
  • reaction is carried out in the presence of at least two equivalents of a carboxylic acid, preferably acetic acid.
  • reaction solution is further washed with an aqueous base such as sodium bicarbonate, sodium carbonate and the like, to remove excess acid.
  • an aqueous base such as sodium bicarbonate, sodium carbonate and the like
  • the compound of formula IV is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium hydroxide on carbon, palladium on carbon and the like, preferably at least 10 weight percent of 20 percent palladium hydroxide on carbon, preferably under atmospheric pressure, in an alcohol solvent, such as lower alkyl alcohol, preferably methanol, preferably at from about 0° to about 40°C, most preferably at room temperature, to form the corresponding compound of formula V.
  • a palladium catalyst such as palladium hydroxide on carbon, palladium on carbon and the like, preferably at least 10 weight percent of 20 percent palladium hydroxide on carbon, preferably under atmospheric pressure
  • an alcohol solvent such as lower alkyl alcohol, preferably methanol, preferably at from about 0° to about 40°C, most preferably at room temperature
  • the desired diastereomer of formula V is preferably isolated by conventional methods known to one skilled in the art, such as recrystallization from an organic solvent such as ethyl acetate, methanol, methyl -t-butyl ether and the like, HPLC or flash chromatography.
  • the compound of formula V is reacted in an acid, such as acetic acid, formic acid, propionic acid, trifluoroacetic acid (TFA) , hydrochloric acid or mixtures thereof, preferably formic acid, preferably in the presence of a hydrosilane such as di lower alkyl silane or tri lower alkyl silane, preferably triethylsilane, at a temperature of in the range of about 40° to about 100°C, preferably at about 80° to about 100°C, to form the corresponding compound of formula la, wherein R 2' is alkyl or aralkyl.
  • an acid such as acetic acid, formic acid, propionic acid, trifluoroacetic acid (TFA) , hydrochloric acid or mixtures thereof, preferably formic acid, preferably in the presence of a hydrosilane such as di lower alkyl silane or tri lower alkyl silane, preferably triethylsilane, at a temperature of in the range of
  • a compound of formula la or a salt thereof, wherein R 2' is alkyl or aralkyl
  • R 2" is hydrogen
  • saponification of the ester by conventional methods, such as reacting the compound of formula la or a salt thereof with lithium hydroxide, sodium hydroxide or potassium hydroxide in a solvent such as tetrahydrofuran (THF) , dimethylformamide (DMF) or methanol.
  • a second crop was obtained by concentrating the filtrate and dissolving the residual oil in 200 mL of ethyl acetate and 20 mL of methanol. After seeding, the solution was stirred for 6h, the second crop was collected by filtration ⁇ r ⁇ d washed with 100 mL of ethyl acetate, then dried in vacu for lh (4.9 g, 13% yield) . Total isolated yield: 31.95 g, 85%.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pyridine Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)

Abstract

A process for the synthesis of a compound of formula (I) wherein R1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl and R2 is hydrogen, alkyl or aralkyl, or salt thereof.

Description

SYNTHESIS OF 3 -AMINO-3-ARYL PROPANOATES
CROSS REFERENCE TO OTHER APPLICATIONS
This application claims the benefit of U. S. Provisional Application No. 60/125,669, filed on March 22, 1999.
FIELD OF THE INVENTION
BACKGROUND OF THE INVENTION
The invention relates to a process of preparing a compound of the formula
Figure imgf000003_0001
I
wherein R1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl and R2 is hydrogen, alkyl or aralkyl, or salt thereof.
Compounds of Formula I are useful as intermediates in the synthesis of, inter alia, compounds described in WO 97/41102. Compounds described in WO 97/41102 are antagonists of the platelet fibrinogen receptor (gp
Ilb/IIIa antagonist) and thus are useful for treating platelet-mediated thrombotic disorders such as arterial and venous thrombosis, acute myocardial infarction, reocclusion following thrombolytic therapy and angioplasty, inflammation, unstable angina and vaso-occlusive disorders. Known methods for preparing compounds of Formula I include an asymmetric Michael addition of lithium (R) -N- (trimethylsilyl) - (1) -phenethylamide to ethyl 3-pyridyl acrylate to give the ethyl β-aminoester disclosed in US Patent 5,254,573. This process results in inefficient formation of lithium amide and difficult removal of N- ( - methylbenzyl ) group .
J. Org. Chem. vol. 61, p. 2222 (1996) discloses a process wherein the lithium enolate of ethyl acetate is added to an enantiomoric sulfinimine, the product of which is purified by chromatography and deprotected under acidic conditions to afford the β-amino ester in greater than 90% ee . The need for chromatographic purification makes this process unattractive for large-scale production.
WO 98/02410 discloses a process of stereoselective addition of the Reformatsky reagent prepared from t- butylbromoacetate to the enantiomeric imine prepared from 3-pyridine carboxaldehyde and (R) -2-phenylglycinol .
Oxidative cleavage of the N- (l-phenyl-2-hydroxy ethyl) group with NaI0 in ethanol followed by acid hydrolysis affords the enantiomerically pure t-butyl β-amino ester. Use of oxidizing agents makes this process unattractive for large-scale production.
WO 97/41102 discloses enzymatic resolution of the (±)β- phenylacetamido acid using penicillin amidase to afford the S-acid. This process, which utilizes enzymes, is inefficient and impractical for large scale production. Thus there exists a need for a process which is compatible with large scale production needs and which achieves acceptable levels of purity and yield.
BRIEF SUMMARY OF THE INVENTION
The invention relates to a process for preparing a compound of the formula
Figure imgf000005_0001
I
wherein R1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl and R2 is hydrogen, alkyl or aralkyl, or salt thereof,
comprising reacting a compound of the formula II
Figure imgf000005_0002
π wherein R1 is as described above and R2' is alkyl or aralkyl, with a compound of the formula III
Figure imgf000005_0003
wherein R5 is hydrogen or alkoxy, under conditions of reduced pressure, such that the reaction solution boils at temperatures of between about 40° and about 65 °C, in an inert solvent, which solvent under reduced pressure is capable of azeotropic removal of water, to form the compound of formula IV,
Figure imgf000006_0001
reacting the compound of formula IV with hydrogen gas in the presence of a palladium catalyst to form the compound of formula V
Figure imgf000006_0002
V
and reacting the compound of formula V to form the compound of formula la or a salt thereof
Figure imgf000006_0003
la
wherein R2' is alkyl or aralkyl If desired, compound la can further be converted to a compound of formula lb or a salt thereof,
Figure imgf000007_0001
lb
wherein R2" is hydrogen via saponification of the ester.
The process of this invention, as described herein, is advantageous over previously disclosed methods in that it is volume efficient, making it suitable for large scale production.
DETAILED DESCRIPTION OF THE INVENTION
As used herein, unless otherwise noted, alkyl whether used alone or as part of a substituent group, include straight and branched chains. For example, alkyl radicals include methyl, ethyl, n-propyl , isopropyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, n-hexyl and the like. Unless otherwise noted, "lower" when used with alkyl means a carbon-chain composition of 1-4 carbon atoms.
As used herein, unless otherwise noted, "alkoxy" shall denote an oxygen ether radical of the above described straight or branched chain alkyl groups. For example, methoxy, ethoxy, n-propoxy, sec-butoxy, t-butoxy, n- hexyloxy and the like.
As used herein alone or as part of a substituent group, unless otherwise noted, "aryl" shall refer to unsubstituted carbocylic aromatic groups such as phenyl, naphthyl, and the like. The aryl group may be substituted with at least one substituent. Suitable substituents on the aryl group are selected independently from the group consisting of halogen, hydroxy, lower alkyl, lower alkoxy, lower aralkyl, -NR3 2, wherein R3 is a lower alkyl; R4CONH, wherein R4 is phenyl or a lower alkyl; and -OC(0)R6 wherein R6 is hydrogen, alkyl or aralkyl.
As used herein, unless otherwise noted, "heteroaryl" shall denote any five or six membered monocyclic aromatic ring structure containing at least one heteroatom selected from 0, N and S or a bicyclic system wherein the monocyclic heteroaryl is fused to an aryl or monocyclic heteroaryl. Examples of suitable heteroaryl groups include, but are not limited to, pyrrolyl , pyridyl, pyrazinyl, pyrimidinyl , pyrazolyl, pyridazinyl, furanyl, pyranyl , imidazolyl, thienyl, oxazolyl, isothiazolyl , isoxazolyl, furazanyl, benzothienyl , benzofuranyl , indolyl , isoindolyl, indolizinyl, indazolyl , purinyl, isoquinolyl , quinolyl , isothiazolyl, and the like. The heteroaryl may be substituted with at least one substituent. Suitable substituents on the heteroaryl group are selected independently from the group consisting of halogen, hydroxy, lower alkyl, lower alkoxy, lower aralkyl, -NR3 2, wherein R3 is a lower alkyl; R4C0NH, wherein R4 is phenyl or a lower alkyl, and
-0C(0)R6 wherein R6 is hydrogen, alkyl or aralkyl; preferably halogen or lower alkyl . The heteroaryl group may be attached at any heteroatom or carbon atom of the ring such that the result is a stable structure.
Preferably, the heteroaryl is selected from the group consisting of pyridyl, pyrimidinyl, furanyl and thienyl. As used herein, unless otherwise noted, "aralkyl" shall mean any lower alkyl group substituted with an aryl group such as phenyl, naphthyl and the like.
As used herein, "halogen" shall mean chlorine, bromine, fluorine and iodine.
As used herein, the notation "*" shall denote the presence of a stereogenic center.
Compound of formula IV, because of the presence of a double bond, can exist in either the cis or the trans configuration or as a mixture of the two configurations.
Compound of formula V, because of the presence of two stereogenic centers can exist as any of four diastereomers, or mixture thereof .
As used herein, with respect to reagents and reaction products, the term "enantiomeric excess or ee" shall mean the excess amount of one enantiomer over another enantiomer. The enantiomeric excess (expressed as a percentage) is calculated as:
[(Amount Enantiomer(D -Amount Enantiomer(2. )/ (Total Amount
Both Enantiomers) ] *100%
Application of the present invention to a mixture of enantiomers of formula III, substantially free of the R enantiomer, will result in the production of a mixture of enantiomers of formula I, substantially free of the R enantiomer. Similarly, application of the present invention to a mixture of enantiomers of formula III, substantially free of the S enantiomer, will result in the production of a mixture of enantiomers of formula I, substantially free of the S enantiomer. Preferably, the enantiomeric excess of the desired enantiomer of formula III is at least 90 percent ee, more preferably at least 98 percent ee, most preferably 99 percent ee .
In a preferred embodiment of the invention, in the compound of formula I, R1 is phenyl, pyrimidyl , unsubstituted or substituted pyridyl, napthyl or 3,5- dichlorophenyl , more preferably 2 -pyridyl, 3 -pyridyl or 4- pyridyl, most preferably 3 -pyridyl. R2 is preferably lower alkyl , more preferably methyl or ethyl .
The invention relates to a process for preparing a compound of the formula I
Figure imgf000010_0001
I
wherein R1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl and R2 is hydrogen, alkyl or aralkyl, or salt thereof,
comprising reacting a compound of the formula II
Figure imgf000010_0002
II
wherein R1 is as described above and R2' is alkyl or aralkyl, with a compound of the formula III
Figure imgf000011_0001
wherein R5 is hydrogen or alkoxy, preferably hydrogen or methoxy, under conditions of reduced pressure, such that the reaction solution boils at temperatures of between about 40° and about 65 °C , in an inert solvent, which solvent under reduced pressure is capable of azeotropic removal of water, to form the compound of formula IV
Figure imgf000011_0002
reacting the compound of formula IV with hydrogen gas in the presence of a palladium catalyst to form the compound of formula V
Figure imgf000011_0003
V and reacting the compound of formula V to form the compound of formula la, wherein R2' is alkyl or aralkyl or a salt thereof .
Figure imgf000012_0001
la
If desired, compound la can further be converted to a compound of formula lb or a salt thereof, wherein R2" is hydrogen via saponification of the ester.
Figure imgf000012_0002
lb
In accordance with the invention, a compound of formula II, a known compound or compound prepared by known methods, (J. Org. Chem . 1975, 40 , 532; J. Org . Chem . 1983, 48 , 5006) is reacted with a compound of formula III, a known compound or compound prepared by known methods , ( Vestn . Mosk . Univ. Ser2 : Khim . 1977, 18 , 446; CAN 88:62074) in the presence of an acid, preferably a carboxylic acid, most preferably acetic acid, under vacuum, preferably the vacuum is adjusted so that the boiling point of the mixture is between about 40° and about 65°C in an inert solvent, which solvent under reduced pressure is capable of azeotropic removal of water, such as xylene, heptane or toluene, preferably toluene, to form the compound of formula IV.
When the process is applied to a compound of formula II wherein R1 is a nitrogen containing heteroaryl, the reaction is carried out in the presence of at least two equivalents of a carboxylic acid, preferably acetic acid.
Preferably, when R1 is a N containing heteroaryl, the reaction solution is further washed with an aqueous base such as sodium bicarbonate, sodium carbonate and the like, to remove excess acid.
The compound of formula IV is reacted with hydrogen gas in the presence of a palladium catalyst such as palladium hydroxide on carbon, palladium on carbon and the like, preferably at least 10 weight percent of 20 percent palladium hydroxide on carbon, preferably under atmospheric pressure, in an alcohol solvent, such as lower alkyl alcohol, preferably methanol, preferably at from about 0° to about 40°C, most preferably at room temperature, to form the corresponding compound of formula V.
The desired diastereomer of formula V is preferably isolated by conventional methods known to one skilled in the art, such as recrystallization from an organic solvent such as ethyl acetate, methanol, methyl -t-butyl ether and the like, HPLC or flash chromatography.
The compound of formula V is reacted in an acid, such as acetic acid, formic acid, propionic acid, trifluoroacetic acid (TFA) , hydrochloric acid or mixtures thereof, preferably formic acid, preferably in the presence of a hydrosilane such as di lower alkyl silane or tri lower alkyl silane, preferably triethylsilane, at a temperature of in the range of about 40° to about 100°C, preferably at about 80° to about 100°C, to form the corresponding compound of formula la, wherein R2' is alkyl or aralkyl. If desired, a compound of formula la or a salt thereof, wherein R2' is alkyl or aralkyl, can further be converted to a compound of formula lb or a salt thereof, wherein R2" is hydrogen, via saponification of the ester by conventional methods, such as reacting the compound of formula la or a salt thereof with lithium hydroxide, sodium hydroxide or potassium hydroxide in a solvent such as tetrahydrofuran (THF) , dimethylformamide (DMF) or methanol.
The following examples describe the invention in greater detail and are intended to illustrate the invention, but not to limit it.
EXAMPLE 1 Methyl N- \ (S) -1- (4-methoxyphenyl ) ethyl1 -3-amino-3- (3- pyridyl ) propanoate
A mixture of methyl nicotinoylacetate (23.6 g, 0.13 mol) and (s) -1- (4-methoxylphenyl) ethylamine (20.0 g, 0.13 mol) was dissolved in toluene (60 mL) to afford a homogeneous solution. Glacial acetic acid (19.5 g, 0.33 mol) was added and resulted in a precipitate formation. The reaction mixture was heated to 62 °C under reduced pressure, the mixture became a clear solution again. The reduced pressure was adjusted to allow the solution to reflux at 62 °C in a steady rate for azeotropic removal of water. The reaction was stopped after 24 h; 1H NMR indicated that the reaction was >90% complete. The solvent was evaporated under reduced pressure at 60°C to afford a brown oil . The crude oil was redissolved in toluene (50 mL) and washed with saturated NaHC03 solution (2 x 100 mL) followed by brine (75 mL) . The organic layer was separated and evaporated to dryness under vacuum at 60 °C to afford 41.1 g of a light brown oil. 1H NMR showed that the crude oil contained the desired product, contaminated with 4.3% toluene and 0.86% water by weight. This crude oil was used directly for the subsequent reduction without further purification.
An analytical sample was obtained by recrystallization from ethyl acetate.
MS m/z (rel intensity): 281.20(50), 313.22 (MH+, 100), 354.24 (MH++MeCN, 40), 432.27(<5).
Elemental analysis, calculated for C18H20N2O3 : C, 69.21; H, 6.45; N, 8.97%. Found: C, 69.27; H, 6.59; N, 8.92%.
EXAMPLE 2 Methyl N- r (S) -1- (4 -methoxyphenyl ) ethyll - (S) -3-amino-3- (3- pyridyl ) propanoate
The crude methyl N- [ (S) -1- (4-methoxyphenyl) ethyl] -3- amino-3- (3 -pyridyl) propenoate, (40.6 g, 130 mmol) was dissolved in methanol (200 mL) and mixed with 20% Pd(OH)2/C (4.1 g) . The mixture was hydrogenated under atmospheric pressure for 3Oh. The mixture was diluted with ethyl acetate (50 mL) and filtered through celite (20 g) to remove the catalyst. The celite was washed with hot (70°C) ethyl acetate (200 mL) . The combined filtrate was concentrated under reduced pressure to near dryness to an oily residue. Crude amine (27.5 g) was dissolved in hot ethyl acetate (40 mL) . The resulting hot yellow solution was filtered and rinsed with 15 mL of hot ethyl acetate. The clear solution was concentrated to <50 mL and allowed to stand at room temperature overnight. The resulting white crystalline solid was collected by filtration and washed with cold ethyl acetate (EtOAc) (-15-20 mL) , then air dried. Yield of isolated solid: 15.5 g. HPLC analysis showed >99% desired diastereomer . A second crop was obtained from the filtrate after concentration to about 20 mL. Yield: 1.7 g identical by HPLC to first crop; total yield: 17.2 g (62.5%)
White crystalline solid, mp 117.3-119.0° C.
MS(ES+) , 315 MH+. Elemental analysis, calculated for C18H22N203 C, 68.77;
H, 7.05; N, 8.91%. Found: C, 68.66; H, 6.95; N, 8.86%.
EXAMPLE 3 Methyl (S) -3-amino-3- (3-pyridyl) propanoate dihvdrochloride
A mixture of methyl N- [ (S) -1- (4-methoxyphenyl) ethyl) - (S) -3-amino-3- (3-pyridyl) propanoate (57.35 g, 0.148 mol) and triethylsilane (25.81 g, 0.222 mol) in formic acid (120 mL) was heated to 90°C (oil-bath) while stirring. The initial suspension became a clear solution after 5 minutes at 90 °C. Heating and stirring was continued for 2h. The reaction mixture was cooled to room temperature and the solvent was removed under reduced pressure at 50°C to give a residual oil. The residual oil was dissolved in ethyl acetate (300 mL) and methanol (100 mL) . The solution was filtered. The filtrate was treated slowly with 9.8M HC1 in methanol (30.2 mL, 0.296 mol) with stirring. The resulting solution was diluted with ethyl acetate (200 mL) and heated on a steam-bath to remove excess methanol until the solution became cloudy. The mixture was then stirred at room temperature overnight and the solid product crystallized from the solution. Ethyl acetate (150 mL) was added to the suspension and the mixture was stirred for another 2h. The solid was collected by filtration and washed with 200 mL of ethyl acetate, then dried in vacu for lh. The desired product was obtained as a white powder (27.05 g, 72% yield) .
HPLC area purity = 98%, ee = 99.4%. mp = 197.5 - 199°C.
A second crop was obtained by concentrating the filtrate and dissolving the residual oil in 200 mL of ethyl acetate and 20 mL of methanol. After seeding, the solution was stirred for 6h, the second crop was collected by filtration <~rιd washed with 100 mL of ethyl acetate, then dried in vacu for lh (4.9 g, 13% yield) . Total isolated yield: 31.95 g, 85%.
HPLC area purity = 90%, ee = 99.8%. mp = 197.5 - 199.5°C.
MS(Esl) m/z 181.2 (MH+), 222.2 (MH++MeCN) Elemental analysis, calculated for: C9H14N2θ2Cl2 : C, 42.71; H, 5.57: N, 11.07; Cl , 28.01. Found: C, 42.68; H, 5.64; N, 11.05; Cl , 28.00.

Claims

We Claim:
1. A process for preparing a compound of the formula I
Figure imgf000018_0001
I wherein R1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl and R2 is hydrogen, alkyl or aralkyl, or a salt thereof,
comprising reacting a compound of the formula II
Figure imgf000018_0002
π
wherein R1 is as described above and R2' is alkyl or aralkyl, with a compound of the formula III
Figure imgf000018_0003
wherein R5 is hydrogen or alkoxy, under conditions of reduced pressure, such that the reaction solution boils at temperatures of between about 40° and about 65°C, in an inert solvent, which solvent under reduced pressure is capable of azeotropic removal of water, to form the compound of formula IV,
Figure imgf000019_0001
reacting the compound of formula IV with hydrogen gas in the presence of a palladium catalyst to form the compound of formula V
Figure imgf000019_0002
and reacting the compound of formula V to form the compound of formula I .
2. A process of Claim 1 wherein the compounds of formula I and III are present in an enantiomeric excess of one enantiomer.
3. A process of Claim 2 wherein the compounds of formula I and III are present in an enantiomeric excess of one enantiomer of at least 90% ee.
4. A process of Claim 3 wherein the compounds of formula I and III are present in an enantiomeric excess of one of the enantiomers of at least 98% ee .
5. A process of Claim 1, wherein R1 is aryl, heteroaryl, mono or di substituted aryl or mono or di substituted heteroaryl, wherein the substituents on the aryl or heteroaryl are independently selected from the group consisting of halogen, hydroxy, lower alkyl, lower alkoxy, lower aralkyl, -NR3 2, wherein R3 is a lower alkyl; R -CONH, wherein R4 is phenyl or a lower alkyl; and -OC (0) R6, wherein R6 is hydrogen, alkyl or aralkyl
6. A process of Claim 5, wherein R1 is phenyl, pyrimidyl , unsubstituted or substituted pyridyl, napthyl or 3,5- dichlorophenyl .
7. A process of Claim 6, wherein R1 is 2 -pyridyl, 3- pyridyl or 4 -pyridyl.
8. A process of Claim 7, wherein R1 is 3-pyridyl.
9. A process of Claim 1, wherein R2 is a lower alkyl.
10. A process of Claim 9, wherein R2 is methyl.
11. A process of Claim 1, wherein R1 is 3-pyridyl and R2 is methyl .
12. A process of Claim 11 wherein the compounds of formula I and III are present in an enantiomeric excess of one enantiomer of at least 90% ee .
13. A process of Claim 11, wherein the inert solvent capable of azeotropic removal of water is xylene, heptane or toluene .
14. A process of Claim 13, further comprising reacting the compound of formula II with the compound of formula III to form the compound of formula IV in the presence of at least two equivalents of a carboxylic acid.
15. A process of Claim 14, wherein the carboxylic acid is acetic acid.
16. A process of Claim 15, further comprising washing the compound of formula IV with an aqueous base to remove excess acid.
17. A process of Claim 15, wherein the palladium catalyst is present in an amount of at least 10 weight percent of 20 percent palladium hydroxide on carbon.
18 . A process of Claim 1 , further comprising separating and isolating the compound of formula V into a desired diastereomer .
19. A process of Claim 15, further comprising separating and isolating the compound of formula V into a desired diastereomer .
20. A process of Claim 15, further comprising reacting the compound of formula V in formic acid, in the presence of a hydrosilane, to form the compound of formula I.
21. A compound of formula IV
Figure imgf000021_0001
wherein R1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl; R2' is alkyl or aralkyl; R5 is hydrogen or hydroxy; or a salt thereof.
22. A compound of formula V
Figure imgf000022_0001
wherein R1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl; R2' is alkyl or aralkyl; R5 is hydrogen or hydroxy; or a salt thereof.
23. A process for preparing a compound of formula I
Figure imgf000022_0002
I wherein R1 is aryl, heteroaryl, substituted aryl or substituted heteroaryl and R2 is hydrogen, alkyl or aralkyl, or a salt thereof,
comprising reacting the compound of formula IV
Figure imgf000022_0003
wherein R1 is as described above, R2' is alkyl or aralkyl and R5 is hydrogen or alkoxy, with hydrogen gas in the presence of a palladium catalyst to form the compound of formula V
Figure imgf000023_0001
and reacting the compound of formula V to form the compound of formula I .
PCT/US2000/007493 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propanoates WO2000056716A1 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CA002367971A CA2367971A1 (en) 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propanoates
JP2000606578A JP2002540101A (en) 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propionate
EP00918213A EP1163223A1 (en) 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propanoates
MXPA01009617A MXPA01009617A (en) 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propanoates.
BR0009856-6A BR0009856A (en) 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propanoates
NZ514379A NZ514379A (en) 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propanoates
SK1359-2001A SK13592001A3 (en) 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propanoates
UA2001096537A UA72755C2 (en) 1999-03-22 2000-03-21 A method for the preparation of 3-amino-3-arylpropanoates and intermediary compounds for realizing the same
KR1020017012070A KR20020015031A (en) 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propanoates
AU39064/00A AU776300B2 (en) 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propanoates
HR20010768A HRP20010768A2 (en) 1999-03-22 2001-10-19 Synthesis of 3-amino-3-aryl propanoates

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12566999P 1999-03-22 1999-03-22
US60/125,669 1999-03-22

Publications (1)

Publication Number Publication Date
WO2000056716A1 true WO2000056716A1 (en) 2000-09-28

Family

ID=22420854

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007493 WO2000056716A1 (en) 1999-03-22 2000-03-21 Synthesis of 3-amino-3-aryl propanoates

Country Status (17)

Country Link
US (3) US6258956B1 (en)
EP (1) EP1163223A1 (en)
JP (1) JP2002540101A (en)
KR (1) KR20020015031A (en)
CN (1) CN1364159A (en)
AU (1) AU776300B2 (en)
BR (1) BR0009856A (en)
CA (1) CA2367971A1 (en)
HR (1) HRP20010768A2 (en)
HU (1) HUP0201263A3 (en)
MX (1) MXPA01009617A (en)
NZ (1) NZ514379A (en)
RU (1) RU2225859C2 (en)
SK (1) SK13592001A3 (en)
UA (1) UA72755C2 (en)
WO (1) WO2000056716A1 (en)
YU (1) YU74501A (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100875A1 (en) 2003-09-18 2009-09-16 Takasago International Corporation Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA72755C2 (en) 1999-03-22 2005-04-15 Ortho Mcneil Pharm Inc A method for the preparation of 3-amino-3-arylpropanoates and intermediary compounds for realizing the same
US7907988B2 (en) * 2002-04-01 2011-03-15 Ilan Elias Method and device for generating a passive movement in a diagnostic device
CN107879963A (en) * 2016-09-29 2018-04-06 中国科学院上海药物研究所 Novel chiral ligands, metallo-chelate, a variety of alpha-non-natural amino acids, the synthetic method of Malawi's promise and its key intermediate

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041102A1 (en) * 1996-05-01 1997-11-06 Ortho Pharmaceutical Corporation Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE58243B1 (en) 1983-12-07 1993-08-11 Lonza Ag A process for the preparation of optically-active 3-amino carboxylic acids
US5254573A (en) * 1991-10-15 1993-10-19 Monsanto Company Substituted heterocyclic derivatives useful as platelet aggregation inhibitors
DK0912495T3 (en) 1996-07-12 2002-05-21 Searle & Co Asymmetric synthesis of chiral beta-amino acids
RU2228929C2 (en) 1999-03-22 2004-05-20 Орто-Макнейл Фармасьютикал, Инк. Method for preparing (3s)-3-amino-3-pyridylpropionic acid and intermediate substance
BR0010652A (en) 1999-03-22 2002-07-16 Ortho Mcneil Pharm Inc Process of preparing [s- (r *, s *)] - beta - [[[1- [1-oxo-3- (4-piperidinyl) propyl] -3-piperi dinyl] carbonyl] amino] -3 -pyridinepropanoic and derivatives
UA72755C2 (en) 1999-03-22 2005-04-15 Ortho Mcneil Pharm Inc A method for the preparation of 3-amino-3-arylpropanoates and intermediary compounds for realizing the same

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997041102A1 (en) * 1996-05-01 1997-11-06 Ortho Pharmaceutical Corporation Carboxamide derivatives of pyrrolidine, piperidine and hexahydroazepine for the treatment of thrombosis disorders

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
F.A.DAVIES ET AL.: "An efficient synthesis of (S)-(+)-Ethyl-beta-Amino-2-pyridinepropanoate using enantiopure sulfinimines", JOURNAL ORGANIC CHEMISTRY., vol. 61, 1996, pages 2222 - 2225, XP002140748 *
P.R.BOVY: "A highly stereoselective michael addition to an alpha, beta-unsaturated ester as the crucial step in the synthesis of a novel beta-amino-acid containing fibrinogen receptor antagonist", JOURNAL ORGANIC CHEMISTRY, vol. 58, no. 27, 1993, pages 7948 - 7951, XP002140749 *
ZHONG H M ET AL: "An efficient stereoselective synthesis of methyl (S)-3-amino-3(3-pyridyl)propanoate", TETRAHEDRON LETTERS,NL,ELSEVIER SCIENCE PUBLISHERS, AMSTERDAM, vol. 40, no. 44, 29 October 1999 (1999-10-29), pages 7721 - 7725, XP004180943, ISSN: 0040-4039 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2100875A1 (en) 2003-09-18 2009-09-16 Takasago International Corporation Asymmetric reductive amination of keto acid derivatives for producing amino acid derivatives

Also Published As

Publication number Publication date
HUP0201263A2 (en) 2002-09-28
AU776300B2 (en) 2004-09-02
NZ514379A (en) 2003-10-31
US6610855B2 (en) 2003-08-26
AU3906400A (en) 2000-10-09
CN1364159A (en) 2002-08-14
HUP0201263A3 (en) 2003-05-28
YU74501A (en) 2004-07-15
JP2002540101A (en) 2002-11-26
MXPA01009617A (en) 2003-07-21
US20020198400A1 (en) 2002-12-26
SK13592001A3 (en) 2002-11-06
HRP20010768A2 (en) 2002-12-31
US6258956B1 (en) 2001-07-10
US20010029300A1 (en) 2001-10-11
HU0201263D0 (en) 2002-05-29
BR0009856A (en) 2002-02-05
RU2225859C2 (en) 2004-03-20
CA2367971A1 (en) 2000-09-28
KR20020015031A (en) 2002-02-27
UA72755C2 (en) 2005-04-15
EP1163223A1 (en) 2001-12-19

Similar Documents

Publication Publication Date Title
JP2002265444A (en) 1-(3-benzyloxypropyl)-5-(2-substituted propyl) indoline derivative and method for using the same
US6258956B1 (en) Synthesis of 3-amino-3-aryl propanoates
CN112645833A (en) Synthesis method of (S) -2, 6-diamino-5-oxohexanoic acid
CN110981934B (en) Synthetic method of argatroban hydrate
RU2228929C2 (en) Method for preparing (3s)-3-amino-3-pyridylpropionic acid and intermediate substance
EP3260442B1 (en) Process for preparation of optically pure n-substituted-3-methoxypropionic acid derivatives
WO2006053440A1 (en) New processes for the preparation of optically pure indoline-2-carboxylic acid and n-acetyl-indoline-2-carboxylic acid
HU203716B (en) Process for producing optically active amino-acids
JP2769058B2 (en) Preparation of cyclopropane derivatives
KR100900573B1 (en) Preparation method of s-atenolol
KR100850558B1 (en) Process for preparing useful in synthesis of atorvastatin
JP4524845B2 (en) Method for producing optically active allyl alcohol derivative having amino group, and optically active compound
KR100413172B1 (en) A process for the preparation of quinolinone derivatives
KR100320772B1 (en) Process for Preparation of (S)-Benzoxazine Derivatives and Process for Racemization of (R)-Benzoxazine Derivatives
JP2003137835A (en) Method for producing (r)-3-hydroxy-3-(2-phenyl)hexanoic acid
JPH10237013A (en) Production of optically active 2-benzylsuccinic acid
FI68830B (en) DL-ELLER D-TRANS-8-FLUORO-5- (P-FLUORPHENYL) -2,3,4,4A, 5,9B-HEXSAHYDRO-1H-PYRIDO (4,3-B) INDOL SOM ANVAENDS SOM MELLANPROTUKT VID FRAMSTAELLNING AV THERAPEUTIC ANVAENDBARA 2-SUBSTITUERADE DL- OCH D-TRANS-8-FLUOR-5- (P-FLUORPHENYL) -2,3,4,4A, 5,9B-HEXSAHYDRO-1H-PYRIDO (4,3-B) INDOLER
CN109456211A (en) A method of synthesis (R) -3- amino -3- (2- nitrobenzophenone) propionic acid
WO2003033473A1 (en) Novel 5-substituted hydantoin derivative and process for producing the same
JP2004059492A (en) Method for producing optically active alpha-(2-aminophenyl)benzylamine
JP2000026384A (en) Production of optically active 4-amino-3-(dihalogeno- substituted phenyl)butyric acid
KR20090053058A (en) New chiral resolving agents and method for isolating chiral isomer using same
JPH10291980A (en) Optically active 4,5-diphenyl-2-imidazolidinone derivative and production of optically active alpha-aminophosphoric acid with the same
WO2006088132A1 (en) Novel pyridine oxide compound, and process for producing carboxylic acid derivative and optically active carboxylic acid derivative with the use of the same

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: P-745/01

Country of ref document: YU

Ref document number: 00807449.6

Country of ref document: CN

AK Designated states

Kind code of ref document: A1

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
ENP Entry into the national phase

Ref document number: 2367971

Country of ref document: CA

Ref document number: 2367971

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 39064/00

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1020017012070

Country of ref document: KR

WWE Wipo information: entry into national phase

Ref document number: PV2001-3432

Country of ref document: CZ

Ref document number: 514379

Country of ref document: NZ

Ref document number: 13592001

Country of ref document: SK

Ref document number: PA/a/2001/009617

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2000 606578

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 2000918213

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: P20010768A

Country of ref document: HR

WWP Wipo information: published in national office

Ref document number: 2000918213

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017012070

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-3432

Country of ref document: CZ

WWW Wipo information: withdrawn in national office

Ref document number: 2000918213

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 39064/00

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1020017012070

Country of ref document: KR

WWR Wipo information: refused in national office

Ref document number: PV2001-3432

Country of ref document: CZ